KPCB PBD Associates, LLC
Known title: 10% OwnerCIK: 0001497523
Associated companies
Transaction History
| SGMT | ▼ Sell | Other | 1,860,712 | — | 7/18/2023 | View on chart |
| SGMT | ▼ Sell | Other | 38,763 | — | 7/18/2023 | View on chart |
| SGMT | ▼ Sell | Other | 38,763 | — | 7/18/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Goldman Sachs reinstates Sell rating on SGMT with $7 target
Goldman Sachs has reinstated a Sell rating on Sagimet Biosciences, setting a price target of $7. This move stands in contrast to the average analyst target of $29.60, highlighting a significant divergence in expert opinions. The stock is currently trading near its 52-week low of $4.50, reflecting the bearish sentiment associated with the new rating.
Goldman Sachs reinstates Sell rating on SGMT with $7 target. Goldman Sachs has reinstated a Sell rating on Sagimet Biosciences, setting a price target of $7. This move stands in contrast to the average analyst target of $29.60, highlighting a significant divergence in expert opinions. The stock is currently trading near its 52-week low of $4.50, reflecting the bearish sentiment associated with the new rating.